Advertisement

Breast Cancer

, Volume 23, Issue 6, pp 945–949 | Cite as

Aromatase inhibitors with or without luteinizing hormone–releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature

  • Sayaka KubaEmail author
  • Mayumi Ishida
  • Masahiro Oikawa
  • Yoshiaki Nakamura
  • Kosho Yamanouchi
  • Eriko Tokunaga
  • Kenichi Taguchi
  • Taito Esaki
  • Susumu Eguchi
  • Shinji Ohno
Case Report

Abstract

The roles of aromatase inhibitors (AIs) and luteinizing hormone–releasing hormone (LH–RH) agonists in the management of male breast cancer remain uncertain, with no reports in Japanese men. We report four Japanese male patients with metastatic breast cancer treated with AIs with or without an LH–RH agonist, and consider the relationship between treatment effect and estradiol (E2) concentration. Three patients were initially treated with AI alone after selective estrogen receptor modulators (SERMs), and one received AIs plus an LH–RH agonist after a SERM. Two patients treated with an AI alone responded, one patient with E2 levels below the lower assay limit and the other with levels above the limit. The other treated with an AI alone experienced progression regardless of the E2 levels below the lower assay limit, however, responded after the addition of an LH–RH agonist. E2 concentrations were related to the efficacy of treatment in one patient. The patient initially treated with an AI plus an LH–RH agonist also responded. No grade 3 or 4 adverse events were observed in any of the patients treated with AIs with or without an LH–RH agonist. AIs with or without an LH–RH agonist offer an effective treatment option for hormone receptor-positive metastatic male breast cancer.

Keywords

Male breast cancer Aromatase inhibitor Metastatic breast cancer 

Notes

Compliance with ethical standards

Conflict of interest

S. Ohno received lecture fees from Chugai and Astrazeneca.

References

  1. 1.
    White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V. Male breast carcinoma: increased awareness needed. Breast Cancer Res. 2011;13(5):219.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012;21(3):242–52.CrossRefPubMedGoogle Scholar
  3. 3.
    NCCN Clinical Practice guideline in Oncology: Breast Cancer. 2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  4. 4.
    Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men. Cancer. 2004;101:51–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137:678–87.CrossRefPubMedGoogle Scholar
  6. 6.
    Rushton M, Kwong A, Visram H, Graham N, Petrcich W, Dent S. Treatment outcomes for male breast cancer: a single-center retrospective case control study. Curr Oncol. 2014;21(3):e400–7.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: a population based study. Cancer. 2013;119(9):1611–7.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Röhl FW, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2013;137(2):465–70.CrossRefPubMedGoogle Scholar
  9. 9.
    Zumoff B, Fishman J, Cassouto J, Hellman L, Gallagher TF. Estradiol transformation in men with breast cancer. J Clin Endocrinol Metab. 1966;26(9):960–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Volm MD. Male breast cancer. Curr Treat Options Oncol. 2003;4(2):159–64.CrossRefPubMedGoogle Scholar
  11. 11.
    Harris AL, Dowsett M, Stuart-Harris R, Smith IE. Role of aminoglutethimide in male breast cancer. Br J Cancer. 1986;54(4):657–60.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Mauras N, O’Brien KO, Klein KO, Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab. 2000;85(7):2370–7.PubMedGoogle Scholar
  13. 13.
    Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A. Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol. 2010;21(6):1243–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, et al. Aromatase inhibitors with or without gonadotropin-releasing hotmone analogue in metastatic male breast cancer: a case series. Br J Cancer. 2013;108(11):2259–63.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Di Lauro L, Vici P, Del Medico P, Laudadio L, Tomao S, Giannarelli D, et al. Breast Cancer Res Treat. 2013;141(1):119–23.CrossRefPubMedGoogle Scholar
  16. 16.
    Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol. 2010;17(5):17–21.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Ann Oncol. 2012;23(6):1471–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99(2):215–20.CrossRefPubMedGoogle Scholar
  19. 19.
    Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–8.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Taketani K, Tokunaga E, Yamashita N, Tanaka K, Akiyoshi S, Okada S, et al. Early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients. Surg Today. 2014;44(10):1841–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Kuba S, Ishida M, Nakamura Y, Taguchi K, Ohno S. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer. Breast Cancer 2016;23(1):128–33.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2016

Authors and Affiliations

  • Sayaka Kuba
    • 1
    Email author
  • Mayumi Ishida
    • 2
  • Masahiro Oikawa
    • 6
  • Yoshiaki Nakamura
    • 2
  • Kosho Yamanouchi
    • 1
  • Eriko Tokunaga
    • 2
  • Kenichi Taguchi
    • 3
  • Taito Esaki
    • 4
  • Susumu Eguchi
    • 1
  • Shinji Ohno
    • 2
    • 5
  1. 1.Department of SurgeryNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
  2. 2.Department of Breast OncologyNational Hospital Organization, Kyushu Cancer CenterFukuokaJapan
  3. 3.Department of PathologyNational Hospital Organization, Kyushu Cancer CenterFukuokaJapan
  4. 4.Department of Clinical OncologyNational Hospital Organization, Kyushu Cancer CenterFukuokaJapan
  5. 5.Clinical Research InstituteNational Hospital Organization, Kyushu Cancer CenterFukuokaJapan
  6. 6.Division of Breast OncologyOikawa HospitalFukuokaJapan

Personalised recommendations